CHU Grenoble Alpes
- Address
- lock Available on a paid plan
Immune System Diseases
The CHU Grenoble Alpes pediatric oncology unit is conducting research on acute lymphoblastic leukemia in children and adolescents, testing new dosing schedules of pegaspargase to improve drug exposure and reduce side effects.
- Optimizing induction therapy for standard‑risk ALL
- Assessing fractionated pegaspargase regimens
- Evaluating toxicity profiles in medium‑risk pediatric patients
With 177 investigators participating, the study aims to enhance survival rates and quality of life for young patients while providing valuable data on pharmacokinetics and tolerance.
Neoplasms
Researchers at CHU Grenoble Alpes are evaluating the combination of olomorasib with immune checkpoint inhibitors for KRAS G12C‑mutant non‑small cell lung cancer, seeking to boost treatment efficacy and monitor safety in patients with unresectable disease.
- Targeted KRAS inhibition strategies
- Combination with PD‑1/PD‑L1 blockade
- Biomarker‑driven patient stratification
This multicenter, open‑label trial integrates detailed immunophenotypic profiling to identify which patients benefit most, aiming to expand therapeutic options for a challenging cancer subtype.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 31 therapeutic areas and 15 of 763 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 716 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 154 by active trials.
lock +153 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +96 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU Grenoble Alpes
lock Showing 1 of 674 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21181) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 763 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 36 | Unknown | 2016-06-23 | 2026-06-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.